195 related articles for article (PubMed ID: 28463229)
1. Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.
Olvedy M; Tisserand JC; Luciani F; Boeckx B; Wouters J; Lopez S; Rambow F; Aibar S; Thienpont B; Barra J; Köhler C; Radaelli E; Tartare-Deckert S; Aerts S; Dubreuil P; van den Oord JJ; Lambrechts D; De Sepulveda P; Marine JC
J Clin Invest; 2017 Jun; 127(6):2310-2325. PubMed ID: 28463229
[TBL] [Abstract][Full Text] [Related]
2. The contrasting oncogenic and tumor suppressor roles of FES.
Greer PA; Kanda S; Smithgall TE
Front Biosci (Schol Ed); 2012 Jan; 4(2):489-501. PubMed ID: 22202072
[TBL] [Abstract][Full Text] [Related]
3. Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.
Mann MB; Black MA; Jones DJ; Ward JM; Yew CC; Newberg JY; Dupuy AJ; Rust AG; Bosenberg MW; McMahon M; Print CG; Copeland NG; Jenkins NA
Nat Genet; 2015 May; 47(5):486-95. PubMed ID: 25848750
[TBL] [Abstract][Full Text] [Related]
4. Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.
Mishra PJ; Mishra PJ; Merlino G
PLoS One; 2016; 11(11):e0165102. PubMed ID: 27846237
[TBL] [Abstract][Full Text] [Related]
5. A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer.
Delfino FJ; Stevenson H; Smithgall TE
J Biol Chem; 2006 Mar; 281(13):8829-35. PubMed ID: 16455651
[TBL] [Abstract][Full Text] [Related]
6. An identity crisis for fps/fes: oncogene or tumor suppressor?
Sangrar W; Zirgnibl RA; Gao Y; Muller WJ; Jia Z; Greer PA
Cancer Res; 2005 May; 65(9):3518-22. PubMed ID: 15867340
[TBL] [Abstract][Full Text] [Related]
7. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.
Wong K; van der Weyden L; Schott CR; Foote A; Constantino-Casas F; Smith S; Dobson JM; Murchison EP; Wu H; Yeh I; Fullen DR; Joseph N; Bastian BC; Patel RM; Martincorena I; Robles-Espinoza CD; Iyer V; Kuijjer ML; Arends MJ; Brenn T; Harms PW; Wood GA; Adams DJ
Nat Commun; 2019 Jan; 10(1):353. PubMed ID: 30664638
[TBL] [Abstract][Full Text] [Related]
8. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
9. The fibroblast growth factor-2 is not essential for melanoma formation in a transgenic mouse model.
Ackermann J; Beermann F
Pigment Cell Res; 2005 Aug; 18(4):315-9. PubMed ID: 16029424
[TBL] [Abstract][Full Text] [Related]
10. Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.
Zhang S; Chitu V; Stanley ER; Elliott BE; Greer PA
Cancer Res; 2011 Feb; 71(4):1465-73. PubMed ID: 21159660
[TBL] [Abstract][Full Text] [Related]
11. Oncogenes in melanoma: an update.
Kunz M
Eur J Cell Biol; 2014; 93(1-2):1-10. PubMed ID: 24468268
[TBL] [Abstract][Full Text] [Related]
12. Fps/Fes protein-tyrosine kinase regulates mast cell adhesion and migration downstream of Kit and beta1 integrin receptors.
Smith JA; Samayawardhena LA; Craig AW
Cell Signal; 2010 Mar; 22(3):427-36. PubMed ID: 19892014
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Wang K; Lim HY; Shi S; Lee J; Deng S; Xie T; Zhu Z; Wang Y; Pocalyko D; Yang WJ; Rejto PA; Mao M; Park CK; Xu J
Hepatology; 2013 Aug; 58(2):706-17. PubMed ID: 23505090
[TBL] [Abstract][Full Text] [Related]
14. Met amplification and tumor progression in Cdkn2a-deficient melanocytes.
Vanbrocklin MW; Robinson JP; Whitwam T; Guilbeault AR; Koeman J; Swiatek PJ; Vande Woude GF; Khoury JD; Holmen SL
Pigment Cell Melanoma Res; 2009 Aug; 22(4):454-60. PubMed ID: 19422607
[TBL] [Abstract][Full Text] [Related]
15. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
[TBL] [Abstract][Full Text] [Related]
16. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
17. FES kinase participates in KIT-ligand induced chemotaxis.
Voisset E; Lopez S; Chaix A; Vita M; George C; Dubreuil P; De Sepulveda P
Biochem Biophys Res Commun; 2010 Feb; 393(1):174-8. PubMed ID: 20117079
[TBL] [Abstract][Full Text] [Related]
18. PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Hu HH; Kannengiesser C; Lesage S; André J; Mourah S; Michel L; Descamps V; Basset-Seguin N; Bagot M; Bensussan A; Lebbé C; Deschamps L; Saiag P; Leccia MT; Bressac-de-Paillerets B; Tsalamlal A; Kumar R; Klebe S; Grandchamp B; Andrieu-Abadie N; Thomas L; Brice A; Dumaz N; Soufir N
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26683220
[TBL] [Abstract][Full Text] [Related]
19. RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb.
Wang J; Hua W; Huang SK; Fan K; Takeshima L; Mao Y; Hoon DS
Oncotarget; 2015 Oct; 6(30):30165-77. PubMed ID: 26334503
[TBL] [Abstract][Full Text] [Related]
20. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
